• In recent days, 10x Genomics experienced an extended winning streak in its stock, lifting its market value by about US$1.10 billion even as commentators highlighted ongoing weakness in operating performance and financial condition.
• This sharp rerating, coming despite concerns about fundamentals and valuation, raises questions about how much of the positive sentiment is grounded in the company’s underlying business trajectory.
• We’ll now examine how this momentum-driven rally, despite weak operating performance, may influence 10x Genomics’ existing investment narrative and risk profile.

Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

10x Genomics Investment Narrative Recap

To own 10x Genomics, you need to believe its single cell and spatial platforms can turn today’s losses into a durable, high value tools business. The recent momentum-driven rally, which lifted market value by about US$1.10 billion despite weak operating performance, does not fundamentally change the key near term catalyst of driving higher consumables usage, nor the central risk that persistent operating losses and high valuation leave little room for execution missteps.

The recent Atera launch is the announcement that feels most connected to this share price spike, because it expands 10x’s spatial biology offering at a time when investor attention is clearly focused on growth stories in this area. If Atera adoption supports higher consumables pull through over time, it could reinforce the bull case around recurring revenue, but until there is clearer evidence in the numbers, the core risk around ongoing losses and pricing pressure remains largely intact.

Yet despite the eye catching rally, one risk that investors should be aware of is how prolonged funding weakness in U.S. academia could...

10x Genomics' narrative projects $709.8 million revenue and $110.2 million earnings by 2029. This requires 3.4% yearly revenue growth and a $153.7 million earnings increase from -$43.5 million today.

Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 35% downside to its current price.

Exploring Other Perspectives

While the recent run up looks strong, the most bearish analysts were expecting only about 2.7 percent annual revenue growth and continued losses, which shows just how differently you and others might view the same business and why it is worth comparing several narratives before deciding what this new rally really means.

Explore 3 other fair value estimates on 10x Genomics - why the stock might be worth as much as 8% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.